Resistance to drug treatment is a critical barrier in cancer therapy. There is an unmet need to
explore cancer hallmarks that can be targeted to overcome this resistance for therapeutic …

Cancer heterogeneity remains a significant challenge for effective cancer treatments. Altered
energetics is one of the hallmarks of cancer and influences tumor growth and drug …

Mass spectrometry imaging (MSI) is an emerging technology in cancer metabolomics.
Desorption electrospray ionization (DESI) and matrix-assisted laser desorption ionization …

Cancer cells possess a highly unique metabolic phenotype, which is characterized by high
glucose uptake, increased glycolytic activity, decreased mitochondrial activity, low …

Metabolic alterations, driven by genetic and epigenetic factors, have long been known to be
associated with the etiology of cancer. Furthermore, accumulating evidence suggest that …

Metabolic reprogramming is a hallmark of cancer and increasing evidence suggests that
reprogrammed cell metabolism supports tumor initiation, progression, metastasis and drug …

The metabolic profiles of breast cancer cells are different from normal mammary epithelial
cells. Breast cancer cells that gain resistance to therapeutic interventions can reprogram …

Background Acute myeloid leukemia (AML) is a hematological malignancy with a dismal
prognosis. For over four decades, AML has primarily been treated by cytarabine combined …

This study aimed to investigate metabolic changes following the acquisition of resistance to
doxorubicin in the triple-negative breast cancer (TNBC) cell line MDA-MB-231. Two drug …

Simple Summary Cancer, but also its treatment, can lead to a reprogramming of cellular
metabolism. These changes are observable in metabolite abundances, which can be …